River Cities is pleased to announce the sale of our investment in TissueTech as part of a minority recapitalization of the company led by Essex Woodlands. TissueTech is a leader in regenerative amniotic tissue-based products for use in ophthalmology, optometry, orthopedics and wound care.
TissueTech is a pioneer of the development and clinical application of amniotic tissue-based products. The company operates as the holding company for Bio-Tissue and Amniox Medical. Amniox Medical develops and markets products for use in the musculoskeletal and wound care markets; Bio-Tissue serves an unmet need for better surgical and therapeutic alternatives for helping eye care professionals manage ocular surface conditions, such as keratitis, recurrent corneal erosions, conjunctivochalasis, pterygium and dry eye. Since the company’s inception, clinicians have performed more than 500,000 human implants of the company’s products and published more than 300 peer-reviewed studies supporting its technology platform. The company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing.
“We were honored to partner with Dr. Scheffer and Amy Tseng to support TissueTech’s mission of advancing human birth tissue in the field of regenerative medicine. The company has grown significantly over the past 5 years, and we anticipate that it will remain a leader in this exciting field,” says Carter McNabb, Managing Director, River Cities.